“Brodalumab in the Treatment of Moderate-to-Severe Psoriasis in Patients Refractory to Anti-Interleukin-17A Therapies: Evaluation of Secondary Endpoints”. SKIN The Journal of Cutaneous Medicine 5, no. 5 (September 13, 2021): 524–529. Accessed May 18, 2025. https://skin.dermsquared.com/skin/article/view/1309.